Moderna Begins Human Trial of Experimental Ebola Vaccine in Canada

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomePMN BusinessModerna Begins Human Trial of Experimental Ebola Vaccine in CanadaModerna Inc. has begun testing an experimental Ebola vaccine in people, marking the second candidate to enter clinical trials against the strain driving the deadliest Ebola outbreak in Democratic Republic of Congo’s history.Author of the article: You can save this article by registering for free here. Or sign-in if you have an account.6(5e53ozid0k4]}u95qx}i08_media_dl_1.png National Institute of Public Hea(Bloomberg) — Moderna Inc. has begun testing an experimental Ebola vaccine in people, marking the second candidate to enter clinical trials against the strain driving the deadliest Ebola outbreak in Democratic Republic of Congo’s history.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe vaccine, which uses the company’s mRNA platform, is being tested as a single shot in about 80 healthy adults in Canada. Initial safety and immune-response data are expected in the coming months, Moderna said Tuesday. The program is backed by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million to fund the phase-1 trial and manufacture additional vaccine doses in parallel so larger studies can begin quickly if the early data are encouraging.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againCEPI is accelerating efforts to develop vaccines against the rare Bundibugyo strain as the outbreak continues to worsen. It spread to a fifth Congolese province last month, while the confirmed death toll has doubled in just over two weeks to 1,707. As of Sunday, authorities had reported 3,802 confirmed cases, making it the largest since the 2013-16 West Africa outbreak.“Getting Moderna’s vaccine candidate into a phase-1 trial this rapidly is a major step forward in the fight against this deadly outbreak,” CEPI’s Chief Executive Officer Richard Hatchett said in a statement. If licensed, Moderna said it would make at least 500,000 doses available to low- and middle-income countries under access pricing.There are no approved vaccines or therapies for Bundibugyo Ebola. Merck & Co.’s Ervebo vaccine, which is licensed against the Zaire strain responsible for Congo’s previous major outbreak and the West Africa epidemic, isn’t approved for Bundibugyo.Still, the Africa Centres for Disease Control and Prevention and its partners plan to present a proposal to a World Health Organization advisory panel this week to consider using the vaccine to help protect frontline health workers, at least 46 of whom have died in the outbreak.Moderna’s vaccine joins an adenovirus-vectored candidate developed by the University of Oxford that entered phase-1 testing last month, while Merck and its partners are preparing a third Bundibugyo vaccine based on the technology behind Ervebo for human studies later this year.—With assistance from Robert Langreth.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.